<DOC>
	<DOCNO>NCT01102101</DOCNO>
	<brief_summary>Postherpetic neuralgia ( PHN ) often associate pain sensory change lead type neuropathic pain modern clinical pain research . It characterize variety sensory pattern , may categorize `` irritable nociceptor '' `` impairment nociceptor '' . At date , several line evidence lead assumption , mechanical hyperalgesia PHN base - least part - central nervous process sensitization . In animal study investigator discover previously unrecognized effect opioids , reversal long-term potentiation ( LTP ) C-fibre synapsis , i.e . opioid-induced depotentiation . In principle , synaptic depotentiation may permanent transient . In study clinically use ultra-short acting MOR agonist remifentanil normalize synaptic strength wash-out drug . At present know whether opioid-induced depotentiation use benefit pain patient . The aim study hypothesis , pain group PHN patient predominant mechanical hyperalgesia reverse intravenous remifentanil plasma target concentration 18ng/ml ( correspond 0.75 µg/kg/min ) 60 minute compare PHN patient sensory type .</brief_summary>
	<brief_title>Effect Opioids Neuropathic Pain Postherpetic Patients</brief_title>
	<detailed_description />
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Neuralgia , Postherpetic</mesh_term>
	<mesh_term>Remifentanil</mesh_term>
	<criteria>Patients suffer PHN . Pain ≥ 4 10 numeric rating scale ( NRS ) Female male patient age 18 Ability understand/write/read german Zoster affect trigeminal , opticus region Any somatic pain strong neuropathic pain Severe progressive disease Acute cardiac decompensation Known cardiac valve dysfunction Known pulmonary hypertension Cardiac conduction disturbance Active herpetic lesion Opioid therapy Asthma bronchial Chronic obstructive pulmonary disease &gt; GOLD II Severe psychiatric condition Abuse alcoholic beverage , drug abuse Negative neuropathic symptom Pregnancy breast feeding Participation clinical trial 2 week precede study Allergy medication use study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Remifentanil</keyword>
	<keyword>Hyperalgesia</keyword>
	<keyword>Zoster</keyword>
	<keyword>Postherpetic neuralgia</keyword>
</DOC>